Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: Association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation

Inflammatory Bowel Diseases

Volumn 18, Issue 2, 2012, Pages 275-283

  Garrity Park, Megan ^a   Loftus Jr , Edward V ^a   Sandborn, William J ^a,b   Smyrk, Thomas C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

myeloperoxidase; RUNX3; tumor necrosis factor alpha; ulcerative colitis associated colorectal cancer

Indexed keywords

MYELOPEROXIDASE; TRANSCRIPTION FACTOR RUNX3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855690333     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21681     Document Type: Article

References (50)

1. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11. (Pubitemid 24195339)
2. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gasteroenterol. 2005; 19 (suppl A): 5A-36A.
3. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: A population based study. N Engl J Med. 1990; 323: 1228-1233. (Pubitemid 20366527)
4. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
5. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G7-17. (Pubitemid 38802113)
6. Loftus EV Jr,. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006; 35: 517-531. (Pubitemid 44307577)
7. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
8. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105. (Pubitemid 47494461)
9. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009; 58: 1226-1233.
10. Hoang P, Crotty B, Dalton HR, et al. Epithelial cells bearing class II molecules stimulate allogeneic human colonic intraepithelial lymphocytes. Gut. 1992; 33: 1089-1093.
11. Liu ZJ, Yadav PK, Su JL, et al. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009; 15: 5784-5788.
12. Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007; 42: 1312-1320. (Pubitemid 47537070)
13. Garrity-Park MM, Loftus EV Jr, Bryant SC, et al. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008; 103: 407-415. (Pubitemid 351248709)
14. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010; 105: 1610-1619.
15. Taniuchi I, Littman DR,. Epigenetic gene silencing by Runx proteins. Oncogene. 2004; 23: 4341-4345. (Pubitemid 38758600)
16. Taniuchi I, Osato M, Egawa T, et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002; 111: 621-633. (Pubitemid 35441245)
17. Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010; 120: 3209-3219.
18. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004; 112: 754-759. (Pubitemid 39435259)
19. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004; 84: 479-484. (Pubitemid 41656475)
20. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006; 66: 6512-6520. (Pubitemid 44085605)
21. Kamikozuru K, Fukunaga K, Hirota S, et al. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol. 2009; 156: 320-327.
22. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 191-199. (Pubitemid 46806228)
23. Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis. 2007; 22: 115-126. (Pubitemid 44964014)
24. Horii J, Hiraoka S, Kato J, et al. Age-related methylation in normal colon mucosa differs between the proximal and distal colon in patients who underwent colonoscopy. Br J Cancer. 2007; 97: 1425-1431.
25. Kundu JK, Surh YJ,. Inflammation: gearing the journey to cancer. Mutat Res. 2008; 659: 15-30.
26. D'Inc×R, Cardin R, Benazzato L, et al. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis. 2004; 10: 23-27. (Pubitemid 38072441)
27. Piedrafita FJ, Molander RB, Vansant G, et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996; 271: 14412-14420.
28. Olson SH, Carlson MD, Ostrer H, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol. 2004; 93: 615-620. (Pubitemid 38766044)
29. Steenport M, Eom H, Uezu M, et al. Association of polymorphisms in myeloperoxidase and catalase genes with precancerous changes in the gastric mucosa of patients at inner-city hospitals in New York. Oncol Rep. 2007; 18: 235-240.
30. Saygili EI, Aksoy N, Pehlivan M, et al. Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma. 2009; 50: 2030-2037.
31. Erdman SE, Rao VP, Poutahidis T, et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A. 2009; 106: 1027-32.
32. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. (Pubitemid 47123518)
33. Fantini MC, Pallone F, Monteleone G,. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol. 2009; 15: 2472-2478.
34. MacDonald TT, Monteleone G, Pender SL,. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol. 2000; 51: 2-9. (Pubitemid 30074296)
35. Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut. 2002; 50 (suppl 3): III60-64. (Pubitemid 34407458)
36. Shimamoto M, Ueno Y, Tanaka S, et al. Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis. World J Gastroenterol. 2007; 13: 5995-6002. (Pubitemid 350238266)
37. Cuadrado E, Alonso M, de Juan MD, et al. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J Gastroenterol. 2008; 14: 1521-1527. (Pubitemid 351460165)
38. Lee HB, Kim JH, Yim CY, et al. Differences in immunophenotyping of mucosal lymphocytes between ulcerative colitis and Crohn's disease. Korean J Intern Med. 1997; 12: 7-15.
39. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol. 2009; 86: 1007-1016.
40. Ullman T, Odze R, Farraye FA,. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis. 2009; 15: 630-638.
41. Xie J, Itzkowitz SH,. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 21: 378-389. (Pubitemid 351320846)
42. Itzkowitz SH, Present DH,. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 314-321. (Pubitemid 40439686)
43. Pohl C, Hombach A, Kruis W,. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000; 47: 57-70. (Pubitemid 30085390)
44. Geboes K,. Ulcerative colitis and malignancy. Acta Gastroenterol Belg. 2000; 63: 279-283.
45. Provenzale D, Onken J,. Surveillance issues in inflammatory bowel disease: ulcerative colitis. J Clin Gastroenterol. 2001; 32: 99-105. (Pubitemid 32113237)
46. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47: 404-409.
47. Levälampi T, Honkanen V, Lahdenne P, et al. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol. 2007; 36: 189-193. (Pubitemid 47174546)
48. Feijóo M, TÃ?nez I, Tasset I, et al. Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Pharmacology. 2009; 83: 211-216.
49. Seidal T, Balaton AJ, Battifora H,. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001; 25: 1204-1207. (Pubitemid 32777722)
50. Roncucci L, Mora E, Mariani F, Bursi S, et al. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2291-2297.